We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ingevity (NGVT) Tops Earnings & Revenue Estimates in Q4
Read MoreHide Full Article
Ingevity Corporation (NGVT - Free Report) recorded a profit (attributable to stockholders) of $42.1 million or 99 cents per share in fourth-quarter 2018, compared with $41.6 million or 97 cents a year ago. Adjusted earnings per share for the reported quarter were $1.07, which surpassed the Zacks Consensus Estimate of 78 cents.
The company’s revenues rose roughly 21% year over year to $278.6 million in the quarter, coming ahead of the Zacks Consensus Estimate of $262.4 million.
Adjusted EBITDA climbed roughly 39% year over year to $73.3 million in the quarter. The chemical maker gained from increased volumes, better price and mix, and reduced raw materials costs.
Ingevity Corporation Price, Consensus and EPS Surprise
For 2018, profit was $169.1 million or $3.97 per share, up roughly 34% from $126.5 million or $2.97 per share recorded in 2017.
Net sales for the year went up around 17% year over year to $1,133.6 million, aided by increased selling prices.
Segment Review
Revenues from the Performance Chemicals division jumped around 20% year over year to $166.1 million in the quarter. Revenues were driven by contributions of Georgia-Pacific pine chemicals acquisition and sales growth in oilfield industry on the back of strong U.S. drilling.
Revenues from the Performance Materials unit went up around 24% to $112.5 million. The growth was supported by sustained adoption of the company’s solutions geared to meet the U.S. EPA Tier 3 and California LEV III automotive emission regulations.
Balance Sheet
Ingevity ended 2018 with cash and cash equivalents of $77.5 million, down around 12% year over year. Long-term debt was $741.2 million, up around 67%.
Outlook
Ingevity expects sales of between $1.30 billion and $1.36 billion for 2019. Adjusted EBITDA for the year has been forecast in the band of $390 million to $410 million. The company expects revenues to increase roughly 18% and earnings to rise around 25% year over year at the mid-point of its guidance factoring in its acquisition of the Capa caprolactone business.
Price Performance
Shares of Ingevity have rallied 49.1% over a year, significantly outperforming the industry’s 2.4% rise.
Zacks Rank and Stocks to Consider
Ingevity currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks worth considering in the basic materials space include Kirkland Lake Gold Ltd. , The Mosaic Company (MOS - Free Report) and Israel Chemicals Ltd. (ICL - Free Report) .
Kirkland Lake Gold has an expected earnings growth rate of 20.9% for the current year and carries a Zacks Rank #1 (Strong Buy). Its shares have shot up 123% in the past year. You can see the complete list of today’s Zacks #1 Rank stocks here.
Mosaic has an expected earnings growth rate of 23.5% for the current year and carries a Zacks Rank #2 (Buy). Its shares have gained 26% in the past year.
Israel Chemicals has an expected earnings growth rate of 10.8% for the current year and carries a Zacks Rank #2. The company’s shares have rallied 35% over the past year.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
Image: Bigstock
Ingevity (NGVT) Tops Earnings & Revenue Estimates in Q4
Ingevity Corporation (NGVT - Free Report) recorded a profit (attributable to stockholders) of $42.1 million or 99 cents per share in fourth-quarter 2018, compared with $41.6 million or 97 cents a year ago. Adjusted earnings per share for the reported quarter were $1.07, which surpassed the Zacks Consensus Estimate of 78 cents.
The company’s revenues rose roughly 21% year over year to $278.6 million in the quarter, coming ahead of the Zacks Consensus Estimate of $262.4 million.
Adjusted EBITDA climbed roughly 39% year over year to $73.3 million in the quarter. The chemical maker gained from increased volumes, better price and mix, and reduced raw materials costs.
Ingevity Corporation Price, Consensus and EPS Surprise
Ingevity Corporation Price, Consensus and EPS Surprise | Ingevity Corporation Quote
FY18 Results
For 2018, profit was $169.1 million or $3.97 per share, up roughly 34% from $126.5 million or $2.97 per share recorded in 2017.
Net sales for the year went up around 17% year over year to $1,133.6 million, aided by increased selling prices.
Segment Review
Revenues from the Performance Chemicals division jumped around 20% year over year to $166.1 million in the quarter. Revenues were driven by contributions of Georgia-Pacific pine chemicals acquisition and sales growth in oilfield industry on the back of strong U.S. drilling.
Revenues from the Performance Materials unit went up around 24% to $112.5 million. The growth was supported by sustained adoption of the company’s solutions geared to meet the U.S. EPA Tier 3 and California LEV III automotive emission regulations.
Balance Sheet
Ingevity ended 2018 with cash and cash equivalents of $77.5 million, down around 12% year over year. Long-term debt was $741.2 million, up around 67%.
Outlook
Ingevity expects sales of between $1.30 billion and $1.36 billion for 2019. Adjusted EBITDA for the year has been forecast in the band of $390 million to $410 million. The company expects revenues to increase roughly 18% and earnings to rise around 25% year over year at the mid-point of its guidance factoring in its acquisition of the Capa caprolactone business.
Price Performance
Shares of Ingevity have rallied 49.1% over a year, significantly outperforming the industry’s 2.4% rise.
Zacks Rank and Stocks to Consider
Ingevity currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks worth considering in the basic materials space include Kirkland Lake Gold Ltd. , The Mosaic Company (MOS - Free Report) and Israel Chemicals Ltd. (ICL - Free Report) .
Kirkland Lake Gold has an expected earnings growth rate of 20.9% for the current year and carries a Zacks Rank #1 (Strong Buy). Its shares have shot up 123% in the past year. You can see the complete list of today’s Zacks #1 Rank stocks here.
Mosaic has an expected earnings growth rate of 23.5% for the current year and carries a Zacks Rank #2 (Buy). Its shares have gained 26% in the past year.
Israel Chemicals has an expected earnings growth rate of 10.8% for the current year and carries a Zacks Rank #2. The company’s shares have rallied 35% over the past year.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>